Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin a chain using different cross-linkers

Victor Ghetie, Mark A. Till, Maria Ana Ghetie, Thomas Tucker, Jim Porter, Eric J. Patzer, James A. Richardson, Jonathan W. Uhr, Ellen S. Vitetta

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In a previous study, we have demonstrated that conjugates containing soluble, recombinant human CD4 (rCD4) and the deglycosylated form of ricin A chain (dgA) (rCD4-dgA) effectively kill a human T cell line infected with the human immunodeficiency virus (HIV) in vitro. In contrast, such conjugates are 100-1000-fold less toxic to uninfected cells. In order to use a rCD4-dgA conjugate effectively in vivo, it was important to demonstrate that (1) it binds to and kills HIV-infected, but not uninfected, human cells, (2) it is stable in the circulation, and (3) it has an optimal therapeutic index (toxicity to animals versus toxicity to target cells). A major factor affecting the efficacy of such conjugates in vitro and in vivo is the nature of the cross-linker between the ligand (rCD4) and the toxin (dgA). In this report, we have prepared rCD4-dgA conjugates using three different cross-linkers. Different methods of purification have been compared by determining the optimal yield, purity, and retention of biological activity (i.e., binding to gp120 and dgA chain activity). The structure of these conjugates as well as their cytotoxicity to target cells in vitro has been analyzed. Finally, we have compared their pharmacokineties, tissue localization, and toxicity in mice.

Original languageEnglish (US)
Pages (from-to)24-31
Number of pages8
JournalBioconjugate Chemistry
Volume1
Issue number1
StatePublished - 1990

Fingerprint

Ricin
Toxicity
Viruses
T-cells
Poisons
Cytotoxicity
Bioactivity
Purification
Animals
Ligands
Cells
Tissue
HIV
T-Lymphocytes
Cell Line

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry

Cite this

Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin a chain using different cross-linkers. / Ghetie, Victor; Till, Mark A.; Ghetie, Maria Ana; Tucker, Thomas; Porter, Jim; Patzer, Eric J.; Richardson, James A.; Uhr, Jonathan W.; Vitetta, Ellen S.

In: Bioconjugate Chemistry, Vol. 1, No. 1, 1990, p. 24-31.

Research output: Contribution to journalArticle

Ghetie, Victor ; Till, Mark A. ; Ghetie, Maria Ana ; Tucker, Thomas ; Porter, Jim ; Patzer, Eric J. ; Richardson, James A. ; Uhr, Jonathan W. ; Vitetta, Ellen S. / Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin a chain using different cross-linkers. In: Bioconjugate Chemistry. 1990 ; Vol. 1, No. 1. pp. 24-31.
@article{2dc082dc7f4b4c0b9d25fe1140da9f27,
title = "Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin a chain using different cross-linkers",
abstract = "In a previous study, we have demonstrated that conjugates containing soluble, recombinant human CD4 (rCD4) and the deglycosylated form of ricin A chain (dgA) (rCD4-dgA) effectively kill a human T cell line infected with the human immunodeficiency virus (HIV) in vitro. In contrast, such conjugates are 100-1000-fold less toxic to uninfected cells. In order to use a rCD4-dgA conjugate effectively in vivo, it was important to demonstrate that (1) it binds to and kills HIV-infected, but not uninfected, human cells, (2) it is stable in the circulation, and (3) it has an optimal therapeutic index (toxicity to animals versus toxicity to target cells). A major factor affecting the efficacy of such conjugates in vitro and in vivo is the nature of the cross-linker between the ligand (rCD4) and the toxin (dgA). In this report, we have prepared rCD4-dgA conjugates using three different cross-linkers. Different methods of purification have been compared by determining the optimal yield, purity, and retention of biological activity (i.e., binding to gp120 and dgA chain activity). The structure of these conjugates as well as their cytotoxicity to target cells in vitro has been analyzed. Finally, we have compared their pharmacokineties, tissue localization, and toxicity in mice.",
author = "Victor Ghetie and Till, {Mark A.} and Ghetie, {Maria Ana} and Thomas Tucker and Jim Porter and Patzer, {Eric J.} and Richardson, {James A.} and Uhr, {Jonathan W.} and Vitetta, {Ellen S.}",
year = "1990",
language = "English (US)",
volume = "1",
pages = "24--31",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin a chain using different cross-linkers

AU - Ghetie, Victor

AU - Till, Mark A.

AU - Ghetie, Maria Ana

AU - Tucker, Thomas

AU - Porter, Jim

AU - Patzer, Eric J.

AU - Richardson, James A.

AU - Uhr, Jonathan W.

AU - Vitetta, Ellen S.

PY - 1990

Y1 - 1990

N2 - In a previous study, we have demonstrated that conjugates containing soluble, recombinant human CD4 (rCD4) and the deglycosylated form of ricin A chain (dgA) (rCD4-dgA) effectively kill a human T cell line infected with the human immunodeficiency virus (HIV) in vitro. In contrast, such conjugates are 100-1000-fold less toxic to uninfected cells. In order to use a rCD4-dgA conjugate effectively in vivo, it was important to demonstrate that (1) it binds to and kills HIV-infected, but not uninfected, human cells, (2) it is stable in the circulation, and (3) it has an optimal therapeutic index (toxicity to animals versus toxicity to target cells). A major factor affecting the efficacy of such conjugates in vitro and in vivo is the nature of the cross-linker between the ligand (rCD4) and the toxin (dgA). In this report, we have prepared rCD4-dgA conjugates using three different cross-linkers. Different methods of purification have been compared by determining the optimal yield, purity, and retention of biological activity (i.e., binding to gp120 and dgA chain activity). The structure of these conjugates as well as their cytotoxicity to target cells in vitro has been analyzed. Finally, we have compared their pharmacokineties, tissue localization, and toxicity in mice.

AB - In a previous study, we have demonstrated that conjugates containing soluble, recombinant human CD4 (rCD4) and the deglycosylated form of ricin A chain (dgA) (rCD4-dgA) effectively kill a human T cell line infected with the human immunodeficiency virus (HIV) in vitro. In contrast, such conjugates are 100-1000-fold less toxic to uninfected cells. In order to use a rCD4-dgA conjugate effectively in vivo, it was important to demonstrate that (1) it binds to and kills HIV-infected, but not uninfected, human cells, (2) it is stable in the circulation, and (3) it has an optimal therapeutic index (toxicity to animals versus toxicity to target cells). A major factor affecting the efficacy of such conjugates in vitro and in vivo is the nature of the cross-linker between the ligand (rCD4) and the toxin (dgA). In this report, we have prepared rCD4-dgA conjugates using three different cross-linkers. Different methods of purification have been compared by determining the optimal yield, purity, and retention of biological activity (i.e., binding to gp120 and dgA chain activity). The structure of these conjugates as well as their cytotoxicity to target cells in vitro has been analyzed. Finally, we have compared their pharmacokineties, tissue localization, and toxicity in mice.

UR - http://www.scopus.com/inward/record.url?scp=0025200063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025200063&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 24

EP - 31

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 1

ER -